source: uk.ibtimes.com
Akers Biosciences has revealed highly positive data following completion of clinical development of the Breath Ketone 'Check' test.ABI designed the Breath Ketone 'Check' as significantly improved, replacement for existing blood and urine based testing methods due to its ability to identify the presence of ketones non-invasively at the earliest stages in a test subject's breath condensate.
The product's accuracy was demonstrated during clinical trials in which Breath Ketone 'Check' results were compared to a standard laboratory method called gas chromatography/liquid chromatography (GC/LC).
This is a technique that analyses a patient's whole blood sample to obtain a quantitative ketone reading.
There was 100% agreement between the testing methodologies from each sample.
President and chief executive Thomas Nicolette said: "The results of this test are the most encouraging and concrete evidence to date that support our belief that ABI's Breath Ketone 'Check' will have a significant improvement in the quality of life for over 220 million diabetic patients around the world at risk of developing ketoacidosis.
"There is an extensive existing market for testing for this condition using cumbersome and invasive methods for which we have shown to be at least as accurate, and within minutes."
The company has applied for a CE-mark to facilitate the initial launch of Breath Ketone 'Check' in the European Union, expected later this year.
Story provided by StockMarketWire.com
